Fidelity Investments
IBO

Fidelity Investments’s Impact BioMedical IBO Stock Holding History

Fidelity Investments’s Portfolio IBO Stock Details IBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$174 Buy
+290
New +$145 ﹤0.01% 5235
2025
Q4 		– Sell
-36
Closed -$24 – 5646
2025
Q3 		$24 Hold
36
– – ﹤0.01% 5307
2025
Q2 		$23 Buy
+36
New +$20 ﹤0.01% 5261

Other funds holding IBO

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VGA
Vanguard Global Advisers Malvern, Pennsylvania $187B AUM
MAC
Mason & Associates (California) Los Angeles, California $619M AUM 29.44% 1-Year Est. Return

Fidelity Investments's IBO Position: Q1 2026 in Review

Fidelity Investments opened a new position in Impact BioMedical (IBO) in Q1 2026: 290 shares worth $174. The stake represents ﹤0.01% of the portfolio and ranks #5235 among its holdings. This is a return to the name: Fidelity Investments previously reported a position in IBO as recently as Q3 2025.

Fidelity Investments first reported a position in IBO in Q2 2025 and has held it in 3 quarters since. 20 funds tracked by Wall St. Rank hold IBO as of Q1 2026.

  • Fidelity Investments held 290 shares of Impact BioMedical worth $174 as of Q1 2026.
  • Impact BioMedical was a new Fidelity Investments position in Q1 2026.
  • Impact BioMedical made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #5235 holding.
  • Fidelity Investments first reported a position in Impact BioMedical in Q2 2025 and has held it in 3 quarters since.
  • 20 funds tracked by Wall St. Rank held Impact BioMedical as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.